Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427854 | 1.00 | BLM (0.49) | BLMRIPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL28690512 | 1.00 | BLM (0.49) | BLMRIPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL12679276 | 1.00 | BLM (0.49) | BLMRIPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL427855 | 1.00 | BLM (0.49) | BLMRIPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL4562897 | 0.87 | RIPK1 (0.47) | BLMRIPK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL19873299 | 0.83 | RIPK1 (0.43) | RIPK1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23009700 | 0.82 | BLM (0.51) | BLMALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL28798055 | 0.82 | RIPK1 (0.47) | RIPK1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL17931647 | 0.82 | RIPK1 (0.51) | RIPK1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1530292 | 0.81 | ALDH1A1 (0.44) | RIPK1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119072335-A | Anti-GLP 1R antibody-drug conjugate comprising GLP1 peptide mimetic and uses thereof | 瑞泽恩制药公司 | 2024-12-03 | — | — | CN | claimed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4687946-A1 | METHODS AND USES FOR TREATING NAUSEA AND EMESIS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4658674-A1 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | Eli Lilly and Company (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024206740-A1 | METHODS AND USES FOR TREATING NAUSEA AND EMESIS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240270821-A1 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2024-08-15 | — | — | US | disclosed |
| WO-2024163535-A1 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4337682-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230183309-A1 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-4144362-A1 | COMPOSITIONS COMPRISING SHORT-ACTING HORMONES FOR TREATING OR PREVENTING OBESITY AND PUMPS COMPRISING SAID COMPOSITION | Adocia (FR) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022241287-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-4077366-A1 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022178366-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | SPITFIRE PHARMA LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4007593-A1 | GIPR-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3993820-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270821-A1 | GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GCGR, GCG | BLM 3635/4885RIPK1 1906/4885ALDH1A1 4227/4885 |
| US-20230183309-A1 | STRUCTURALLY-STABILIZED GLUCAGON-LIKE PEPTIDE 1 PEPTIDES AND USES THEREOF | GLP1R, IAPP, GPR119 | BLM 3060/4885RIPK1 2125/4885ALDH1A1 4654/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | BLM 1378/4885RIPK1 1645/4885ALDH1A1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.